Forest Laboratories, Glenmark cardiovascular news
Forest and Glenmark settled a March 2012 patent suit claiming Glenmark's ANDA for a generic version of hypertension drug Bystolic nebivolol infringes Forest's U.S. Patent No. 6,545,040. The patent covers methods of treating hypertension with Bystolic and expires in December 2021. Under the settlement, Glenmark will receive a license to market its generic version of Bystolic by the later of either three months prior to the expiration of the '040 patent, including any extension and/or pediatric exclusivities, or the date FDA approves an ANDA or earlier in undisclosed circumstances. The suit was filed in the U.S. District Court for the District of Delaware and transferred to the U.S. District Court for the Northern District of Illinois in June 2012. Late last year, Forest settled similar cases against several other generics companies. Forest said litigation against Amerigen Pharmaceuticals Ltd. (Lyndhurst, N.J.) and Watson Pharmaceuticals Inc. (NYSE:WPI, Parsippany, N.J.) is ongoing in the Illinois court (see BioCentury, March 19, 2012; Nov. 5, 2012 & Dec. 10, 2012). ...